Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Dextranomer-hyaluronic acid injection safe, effective in vesicoureteral reflux treatment

13 Apr 2018

Endoscopic injection of dextranomer/hyaluronic acid appears to safely and effectively eradicate high-grade vesicoureteral reflux (VUR), according to a study.

A total of 851 paediatric patients (median age 2.3 years) underwent endoscopic correction of high-grade VUR using dextranomer/hyaluronic acid. Reflux was unilateral in 415 patients and bilateral in 436. There were 1,287 refluxing units in the entire population: grade IV in 1,153 (89.6 percent) and grade V in 134 (10.4 percent). Results for 99mtechnetium-dimercaptosuccinic acid imaging showed renal scarring in 317 patients (37.3 percent).

Follow-up assessments included ultrasound and voiding cystourethrogram performed 3 months postintervention, and renal ultrasound annually thereafter. Median follow-up was 8.5 years.

Overall reflux resolution rate following the first endoscopic injection was 69.5 percent (70.4 percent in grade IV and 61.9 percent in grade V). Reflux resolved after a second injection in 20.1 percent and after a third in 10.4 percent. Persistent reflux after initial treatment occurred with greater frequency in infants <1 year and in cases with renal scarring.

There were no reports of significant postoperative complications, and no patient required ureteral reimplantation. However, following reflux resolution, 43 patients developed febrile urinary tract infections (UTIs). These infections occurred in the first year for 24 patients, in the second year for 15 and after ≥3 years for four.

In the group of patients who developed febrile UTIs, six had reflux recurrence and eight had neocontralateral grade III reflux, which was successfully resolved with a single endoscopic injection of dextranomer/hyaluronic acid.

Based on the present data, the researchers recommend use of endoscopic injection of dextranomer/hyaluronic, a minimally invasive outpatient procedure, in the first-line treatment of children with grade IV-V reflux. Of note, the procedure can be easily repeated in cases of failure with a high subsequent resolution rate.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.